Abstinence at end of treatment ‐ homozygous minor · people who smoke
Active NRT may leads to higher abstinence at end of treatment ‐ homozygous minor compared with placebo ‐ rs1051730 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT showed no clear difference in end of treatment compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (moderate certainty).
1 finding from 1 review
End of treatment ‐ homozygous major · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous major compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment ‐ heterozygous · people who smoke
Active NRT leads to higher end of treatment ‐ heterozygous compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (high certainty).
1 finding from 1 review
End of treatment ‐ homozygous minor · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
Active range of motion of the ankle joint · children with ITW gait
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Patient outcome: treatment adherence: not adherent at · patients with schizophrenia or related psychoses
It is very uncertain whether active education + Support for implementation changes patient outcome: treatment adherence: not adherent at compared with routine care or Passive dissemination (very low certainty).
1 finding from 1 review
Participant‐reported cure or improvement: immediately after treatment · overactive bladder
It is very uncertain whether summary of findings table ‐ Bladder training changes participant‐reported cure or improvement: immediately after treatment compared with no treatment (very low certainty).
1 finding from 1 review
Symptom‐ and condition‐related quality of life: immediately after treatment · overactive bladder
1 finding from 1 review
Number of any adverse events: immediately after treatment · overactive bladder
1 finding from 1 review
Participant‐reported satisfaction: immediately after treatment · overactive bladder
1 finding from 1 review
Episodes of urinary incontinence in a 24‐hour period · overactive bladder
1 finding from 1 review
Number of urgency episodes per 24 hours: immediately after treatment · overactive bladder
1 finding from 1 review
Number of micturition episodes per 24 hours: immediately after treatment · overactive bladder
1 finding from 1 review
Overactive bladder symptoms cured or improved · Adults with overactive bladder (OAB)
1 finding from 1 review
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found